Seb läkemedelsfond

We, at SEB Funds AB, will merge the Luxembourg-domiciled SEB Concept Biotechnology with the Swedish-domiciled SEB Läkemedelsfond. The merger will be effective 8 September 2025. 

The merger aims to simplify and streamline the fund offering while enhancing the efficiency of fund management.

How you as an investor are affected

This is a merger by absorption, whereby the merging fund's holdings, including its assets and liabilities, will be transferred to the receiving fund.

Past performance is not necessarily a guide to future performance; unit prices may fall as well as rise.

The videos and white papers displayed on this page have not been devised by The Financial Times Limited ("FT"). Any prospectus you view on this page has not been approved by FT and FT is not responsible for the content of the prospectus.

The information made available to you does not constitute the giving of investment advice or an offer to sell or the solicitation of an offer to buy any security of any enterprise in any jurisdiction.

Den största skillnaden mellan fonderna är att den överlåtande fonden har ett mer fokuserat investeringsområde, inriktat på biotekniksektorn, som är en undersektor av den bredare hälso- och sjukvårdssektorn som den mottagande fonden investerar i.

Berörda andelsklasser och ISIN

Handelsinformation

Önskar du lösa in ditt innehav i fonden innan sammanläggningen gäller följande:

Viktiga datum

29 augusti 2025: Sista möjligheten om du vill sälja den överlåtande fonden innan sammanläggningen är före bryttiden detta datum
8 september 2025: Sammanläggningen genomförs

Vi tar som vanligt inte ut någon avgift vid köp eller försäljning i fonden.

The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. The securities listed above are not registered and will not be registered for sale in the United Sates and cannot be purchased by U.S.

investors as the securities can only be purchased in jurisdictions where they have been registered for sale or where an exemption from registration applies. The offer, sale or delivery of the securities within the United States or to, or for the account or benefit of, U.S. Persons is not permitted except pursuant to an exemption from registration under U.S.

securities laws, which may not be available; and the availability of the information through the website does not alter or change the persons eligible to purchase the security.

All managed funds data located on FT.com is subject to the FT Terms & Conditions

All content on FT.com is for your general information and use only and is not intended to address your particular requirements.

Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Pricing for ETFs is the latest price and not "real time".

Försäljning eller byte kan däremot medföra skatteeffekter för dig, vänligen kontakta din rådgivare för mer information.